Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ

Enterprise software veteran to lead Tacton's united commercial organization and partner expansion worldwide. Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutio ...

Calls Growing For US Authorities To Commute Christa Pike's Death Sentence

Calls are growing for U.S. authorities to commute the death sentence of Tennessee death row inmate Christa Pike.The UN human rights chief and nine independent rights experts ...

Reportable, Inc.: Healthspan Action Coalition and Leading Italian Organizations Announce Global Collaboration

The Healthspan Action Coalition (HSAC) today announced a strategic international collaboration with a coalition of prominent Italian organizations ...

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer

Appointments expand emnify executive team to accelerate global growth emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and ...

GLP-1 Drugs May Be Linked To Nail Changes And Hair Loss, Study Finds

People using GLP-1 receptor agonists may be more likely to experience certain nail and hair problems, according to a study that examined the potential skin-related effects ...

AI/ML Innovations Inc.: AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement

TORONTO, ON / ACCESS Newswire / October 2, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence and neural-network-bas ...

Teva Pharmaceutical Industries Ltd: Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

Based on a post hoc analysis, a majority of participants (~70%) experienced clinically meaningful tic reduction within 8 weeks of starting ecopipamAn interim 18-month analysis of an ongoing open-label ...